PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics (PTCT) director reported Rule 10b5-1 trades. On 10/30/2025, the insider exercised 12,000 stock options at $38.1 per share and sold 12,000 common shares at $69.5. The filing also lists a separate sale of 3,666 shares at $69.5. After these transactions, the insider reported 6,666 shares held directly.
The trades were effected pursuant to a written Rule 10b5-1 plan adopted on March 4, 2025. The exercised options were currently exercisable and carry an expiration date of January 6, 2032.
PTC Therapeutics insider Mark Elliott Boulding, Executive Vice President and Chief Legal Officer, reported transactions on 10/07/2025 under a written Rule 10b5-1 plan adopted on 12/05/2024. He acquired a stock option for 3,375 shares with an exercise price of $38.10 and an expiration date of 01/06/2032. On the same date he sold a total of 3,375 common shares in three weighted-average-price tranches for aggregate proceeds at weighted prices of $62.89, $63.80, and $64.97 (ranges disclosed per tranche). After these transactions he beneficially owned 103,901 shares.
PTC Therapeutics director Emma Reeve reported multiple transactions on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/04/2025. The filings show a mix of purchases and sales in the issuer's common stock and related stock options. Across the trades on that date the reporting person acquired 10,000 shares and additional option grants totaling 25,562 option rights at exercise prices of $33.02 and $33.63, while executing several sales at weighted average prices in the mid-$60s. The director's reported direct beneficial ownership after the transactions is 10,332 shares.
The transactions were effected pursuant to the 10b5-1 plan and several sale prices are disclosed as weighted averages across multiple trades; detailed per-trade price breakdowns are offered on request to regulators or the issuer.
PTC Therapeutics director Allan Steven Jacobson reported offsetting transactions executed on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/12/2025. He exercised 12,000 stock options with an exercise price of $30.86, receiving 12,000 shares, and simultaneously sold 12,000 shares at $65.00. After the trades his direct holdings changed to 29,451 shares before the sale and 17,451 shares following the sale; the derivative table shows the option became exercisable on 10/03/2025 and expires on 01/03/2026. The form is filed by one reporting person and was signed by an attorney-in-fact on 10/07/2025.
PTC Therapeutics insider transactions: an executive exercised stock options and sold an equal number of shares under a pre-existing trading plan. On 10/03/2025 and 10/06/2025, the reporting person exercised stock options with an exercise price of $39.42 and acquired 24,921 shares in aggregate. The filing shows sales of 24,921 shares executed at weighted average prices ranging roughly from $64.00 to $67.29, producing reported sale prices such as $64.43, $65.47, and $66.44. Following these transactions the reporting person beneficially owns 103,901 shares.
The filing notes the trades were effected pursuant to a written Rule 10b5-1 plan adopted on 12/05/2024, and that the underlying options were originally granted on 01/05/2023 with a vesting schedule that began on 01/05/2024. The pattern—exercise at $39.42 and near-immediate sales at ~$64–$67—is consistent with option exercises followed by planned sales, leaving the reporting person with 103,901 shares after the reported activity.
PTC Therapeutics insider Neil G. Almstead completed matched option exercises and open-market sales totaling 55,000 shares on 10/03/2025. The transactions were executed under a Rule 10b5-1 plan adopted on 12/10/2024, and consisted of two option exercises at an exercise price of $30.86 (total 55,000 shares acquired) and multiple sales at weighted-average prices ranging from $65.45 to $67.16. After these actions the reporting person directly holds 100,625 shares and the reporting persons spouse holds 6,179 shares indirectly; the report also notes 272 shares purchased through the employee stock purchase plan for the period ended 6/30/2025.
The filing shows the exercises funded sales executed the same day (net zero change from the matched option exercises and sales), and the reporting person certified the trades via an attorney-in-fact signature on 10/07/2025.
Form 144 notice reports a proposed sale of 3,375 common shares by an affiliated person, scheduled approximately on 10/07/2025 through Fidelity Brokerage Services LLC on NASDAQ. The filing records the securities were acquired as an option granted on 01/07/2022 and that payment on the planned sale will be in cash. The form also lists five recent open-market sales by the same seller totaling 73,983 shares across dates from 08/15/2025 to 10/06/2025 with individual gross proceeds shown (largest single-day gross proceeds $1,508,093.64 on 09/12/2025).
The document includes the seller's representation about lack of undisclosed material adverse information and mentions Rule 10b5-1 plan language but provides no further corporate financial metrics or forward guidance. The filing is procedural and focused on disclosure of insider sales activity rather than company operational results.
Form 144 filing for PTC Therapeutics (PTCT) reporting a proposed sale of 2,266 common shares held by the named person through a broker on 10/06/2025, with an aggregate market value of $147,453.25. The securities were acquired as an option granted on 01/05/2023 and the intended sale is to be settled for cash. The filer also disclosed multiple recent sales by the same person during the prior three months: 2,813 shares on 08/15/2025, 22,664 shares on 09/11/2025, 24,585 shares on 09/12/2025, and 22,655 shares on 10/03/2025, generating gross proceeds in the six-figure to low seven-figure range. The filing includes the broker name (Fidelity Brokerage Services LLC) and indicates trades on NASDAQ.
PTC Therapeutics, Inc. submitted a Form 144 disclosing a proposed sale of 22,655 common shares through Fidelity Brokerage Services LLC on 10/03/2025 with an aggregate market value of $1,491,104.96. The filing reports the shares were acquired under an option granted on 01/05/2023 and will be sold for cash. The issuer's outstanding shares are listed as 79,438,094.
The filing also lists prior sales by the same person in the past three months: 2,813 shares on 08/15/2025 (gross proceeds $136,646.54), 22,664 shares on 09/11/2025 (gross proceeds $1,382,537.63), and 24,585 shares on 09/12/2025 (gross proceeds $1,508,093.64). The filer attests there is no undisclosed material adverse information.
PTC Therapeutics (PTCT) submitted a Form 144 notice for a proposed sale of 25,562 common shares with an aggregate market value of $1,685,979.27, planned for 10/03/2025 on NASDAQ. The shares correspond to option exercises granted on 12/14/2018 (8,650 shares), 01/22/2019 (6,912 shares) and 01/05/2023 (10,000 shares); payment for these shares is shown as cash on 10/03/2025. The filing lists a recent sale on 09/11/2025 of 15,705 common shares that generated $934,447.50 in gross proceeds by a seller identified as Emma Reeve. The notice includes the required representation that the signer does not possess undisclosed material adverse information about the issuer.